Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD

Blood (2019) 134 (Supplement_1): 1536.

https://doi.org/10.1182/blood-2019-124515

Published: 2019

Journal Articles

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

Robert J. Kreitman, MD, Philippe Moreau, Martin Hutchings, MD, Anas Gazzah, MD, Jean-Yves Blay, MD PhD, Zev A. Wainberg, MD, Alexander Stein, MD, Sascha Dietrich, MD, Maja J.A. de Jonge, MD, Wolfgang Willenbacher, MD, Jacques De Greve, MD, Evgeny Arons, PhD, Farhad Ravandi, MD, Fatima Rangwala, Paul Burgess, Bijoyesh Mookerjee, Vivek Subbiah, MD

Blood (2018) 132 (Supplement 1): 391.

https://doi.org/10.1182/blood-2018-99-113135

Published: 2018

Journal Articles

Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing

Evgeny Arons, PhD, Daniel Gorelik, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Mark Sokolsky, Hong Zhou, Nai Shun (nancy) Yao, MD, Shannon Marshall, PhD, Katherine Potocka, Erin Fykes, Ira Pastan, MD, Robert J. Kreitman, MD

Blood (2018) 132 (Supplement 1): 1861.

https://doi.org/10.1182/blood-2018-99-113419

Published: 2018

Journal Articles

Increased Expression of Myc in Hairy Cell Leukemia, and Cell-Sensitivity to JQ1

Evgeny Arons, PhD, Hong Zhou, Yonghong Wang, PhD, Daniel Edelman, PhD, Robert J. Kreitman, MD, Holly S Stevenson, Josh J Waterfall, PhD, Paul S. Meltzer, MD PhD

Blood (2016) 128 (22): 5112.

https://doi.org/10.1182/blood.V128.22.5112.5112

Published: 2016

Journal Articles

High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome

Robert J. Kreitman, MD, Evgeny Arons, PhD, Martin S Tallman, MD, Robak Tadeusz, MD PhD, Steven Coutre, MD, Wyndham H Wilson, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Mark Lanasa, MD PhD, David JP FitzGerald, PhD, Ira Pastan, MD

Blood (2015) 126 (23): 4161.

https://doi.org/10.1182/blood.V126.23.4161.4161

Published: 2015

Journal Articles

Molecular Evidence of Ongoing Antigen Driven Somatic Hypermutation in the Natural History of Classic and Variant Hairy Cell Leukemia

Evgeny Arons, PhD, Sarah Davies, Katherine Still, Nathan Chai, Katherine Potocka, Hong Zhou, Robert J. Kreitman, MD

Blood (2015) 126 (23): 2648.

https://doi.org/10.1182/blood.V126.23.2648.2648

Published: 2015

Journal Articles

Series of Hairy Cell Leukemia Patients with Co-Existent Plasma Cell Disorders

Neha Korde, MD, Sham Mailankody, MD, Evgeny Arons, PhD, Raul C. Braylan, MD, Mark Raffeld, MD, Elizabeth Maestri, RN, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Ola Landgren, MD PhD, Irina Maric, MD, Robert J. Kreitman, MD

Blood (2014) 124 (21): 5647.

https://doi.org/10.1182/blood.V124.21.5647.5647

Published: 2014

Journal Articles

Minimal Residual Disease By Patient-Specific Taqman Real Time PCR in Newly Diagnosed Hairy Cell Leukemia Patients Randomized to Initial Vs Delayed Rituximab in Combination with Cladribine

Evgeny Arons, PhD, Katherine Still, BS, Sarah Davies, BS, Hong Zhou, BS, Robert J. Kreitman, MD

Blood (2014) 124 (21): 1747.

https://doi.org/10.1182/blood.V124.21.1747.1747

Published: 2014

Journal Articles

Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

Robert J. Kreitman, MD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD, PhD, Wyndham H Wilson, MD, PhD, David J. P. FitzGerald, PhD, Ira Pastan, MD

Blood (2013) 122 (21): 2871.

https://doi.org/10.1182/blood.V122.21.2871.2871

Published: 2013

Journal Articles

Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL

Mariela Sivina, PhD, Robert J. Kreitman, MD, Evgeny Arons, PhD, Joseph J. Buggy, PhD, Farhad Ravandi, MD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 1802.

https://doi.org/10.1182/blood.V120.21.1802.1802

Published: 2012

Journal Articles

Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.

Robert J. Kreitman, MD, Evgeny Arons, PhD, Sapolsky Jeffrey, Laura Roth, Hong Zhou, BS, Maryalice Stetler-Stevenson, MD, PhD, Wyndham H. Wilson, MD, PhD, Mark Raffeld, MD, David J. P. FitzGerald, PhD, Ji Fei, PhD, Ramy Ibrahim, MD, Ira Pastan, MD

Blood (2012) 120 (21): 2896.

https://doi.org/10.1182/blood.V120.21.2896.2896

Published: 2012

Journal Articles

The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.

Evgeny Arons, PhD, Laura Roth, Sharon Adams, CHS, Jeffery Sapolsky, Ira Pastan, MD, Robert J. Kreitman, MD

Blood (2012) 120 (21): 2488.

https://doi.org/10.1182/blood.V120.21.2488.2488

Published: 2012

Journal Articles

Presence and Absence of the BRAF V600E Mutation in Hairy Cell Leukemia and Its Variants

Robert J. Kreitman, MD, Liqiang Xi, MD, Winnifred Navarro, BS, Maryalice Stetler-Stevenson, MD, PhD, Evgeny Arons, PhD, Mark Raffeld, MD

Blood (2011) 118 (21): 931.

https://doi.org/10.1182/blood.V118.21.931.931

Published: 2011

Journal Articles

Bendamustine and Rituximab for the Treatment of Multiply Relapsed Hairy Cell Leukemia,

Robert J. Kreitman, MD, Maryalice Stetler-Stevenson, MD, PhD, Wyndham H. Wilson, MD, PhD, Sapolsky Jeffrey, Laura Roth, Evgeny Arons, PhD

Blood (2011) 118 (21): 3909.

https://doi.org/10.1182/blood.V118.21.3909.3909

Published: 2011

Journal Articles

Interim Results of Secondary Endpoints From a Randomized Trial of Cladribine with Early Vs Delayed Rituximab for Treatment of Early Hairy Cell Leukemia

Robert J Kreitman, MD, Wyndham H. Wilson, MD, PhD, Hong Zhou, BS, Mark Raffeld, MD, Maryalice Stetler-Stevenson, MD, PhD, Evgeny Arons, PhD

Blood (2011) 118 (21): 2856.

https://doi.org/10.1182/blood.V118.21.2856.2856

Published: 2011

Journal Articles

Molecular Characteristic of Variant and Classic Hairy Cell Leukemia.

Evgeny Arons, PhD, Tara Suntum, Joel Sunshine, Anna Orthwein, Inger Margulies, Maryalice Stetler-Stevenson, MD, PhD, Robert Kreitman, MD

Blood (2008) 112 (11): 1063.

https://doi.org/10.1182/blood.V112.11.1063.1063

Published: 2008

NARROW

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing

Increased Expression of Myc in Hairy Cell Leukemia, and Cell-Sensitivity to JQ1

High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome

Molecular Evidence of Ongoing Antigen Driven Somatic Hypermutation in the Natural History of Classic and Variant Hairy Cell Leukemia

Series of Hairy Cell Leukemia Patients with Co-Existent Plasma Cell Disorders

Minimal Residual Disease By Patient-Specific Taqman Real Time PCR in Newly Diagnosed Hairy Cell Leukemia Patients Randomized to Initial Vs Delayed Rituximab in Combination with Cladribine

Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL

Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.

The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.

Presence and Absence of the BRAF V600E Mutation in Hairy Cell Leukemia and Its Variants

Bendamustine and Rituximab for the Treatment of Multiply Relapsed Hairy Cell Leukemia,

Interim Results of Secondary Endpoints From a Randomized Trial of Cladribine with Early Vs Delayed Rituximab for Treatment of Early Hairy Cell Leukemia

Molecular Characteristic of Variant and Classic Hairy Cell Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only